UCB's Global Corporate Website
Welcome to UCB in the United States

Oct

12

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Mar

18

Bimekizumab Phase 3 Data in Hidradenitis Suppurativa Show Clinically Meaningful, Deep and Maintained Response over 48 Weeks

Dec

09

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Jun

07

Disease Spotlight: Hidradenitis Suppurativa

At UCB, people are at the heart of everything we do and part of our commitment to delivering impactful solutions for people whose lives have been challenged by severe disease is by deeply understanding their disease. This week is Hidradenitis Suppurativa (HS) Awareness Week and we’re sharing information on this lesser-known inflammatory, chronic autoimmune skin disease.